ArticleFrontiers in immunology2026
An integrated SII-PNI immune-nutritional scoring system predicts efficacy and immune-related adverse events in locally advanced gastric cancer patients undergoing neoadjuvant immunotherapy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low-dose radiotherapy combined with immune checkpoint inhibitors in advanced malignancies: a real-world exploratory study.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed treatment of locally advanced gastric cancer (LAGC), yet response heterogeneity and immune-related adverse events (irAEs) remain major challenges. Systemic inflammation and nutritional status critically modulate antitumor immunity. This study evaluated the dual predictive value of a combined Systemic Immune-Inflammation Index and Prognostic Nutritional Index (SII-PNI) score for therapeutic efficacy and safety in LAGC patients receiving neoadjuvant PD-1/PD-L1 inhibitor-based therapy. Methods: We retrospectively analyzed 276 LAGC patients who received PD-1/PD-L1 inhibitor-based neoadjuvant immunotherapy (January 2019-December 2021). Blood samples were collected within 7 days before treatment initiation. Optimal cut-off values for SII and PNI were determined via ROC analysis to construct the SII-PNI score (Score 0-2). Primary endpoints were disease-free survival (DFS), overall survival (OS), tumor response (RECIST 1.1), and irAE incidence. Results: The optimal cut-off values were 736.2 for SII and 48.5 for PNI. Patients with a high SII-PNI score (Score 2) exhibited significantly poorer objective response rates (ORR) compared to the low-risk Score 0 group (22.6% vs. 71.2%, P < 0.001). The SII-PNI score demonstrated superior predictive accuracy for immunotherapy response (AUC = 0.750) compared to PD-L1 CPS (AUC = 0.711) and Tumor Mutational Burden (TMB, AUC = 0.625). Multivariate Cox analysis identified the SII-PNI score as an independent prognostic factor; compared to Score 0, patients with Score 2 faced a more than threefold increased risk of disease recurrence (HR = 3.45, 95% CI: 2.40-4.95, P < 0.001) and mortality (HR = 3.15, 95% CI: 1.85-5.36, P < 0.001). Furthermore, the high-risk group (Score 2) had a significantly higher incidence of severe (Grade 3-4) irAEs compared to the low-risk group (28.6% vs. 3.6%, P < 0.001). Conclusions: The SII-PNI score is a robust, non-invasive, and economically accessible biomarker that effectively stratifies outcomes in gastric cancer patients receiving neoadjuvant immunotherapy. It serves as a dual predictor for both poor therapeutic response and increased toxicity, outperforming traditional biomarkers like PD-L1 CPS. This scoring system holds promise for guiding personalized treatment strategies and optimizing patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.